secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0001193125-24-242808
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell to acquire ImmPACT Bio for $30M cash + 37.5M shares; discontinues LYL797, LYL845
--------------------------------------------------------------------------------

- Upfront consideration: $30M cash (adjusted for ImmPACT's ~$16M cash) and 37.5M Lyell shares.
- Contingent consideration: up to 12.5M additional shares on clinical/regulatory milestone + low single-digit US royalty on IMPT-314.
- Pipeline prioritization: discontinuation of LYL797 (ROR1 CAR T), LYL845 (TIL), and preclinical TIL programs.
- Focus on IMPT-314 (dual CD19/20 CAR T) and LYL119 (next-gen ROR1 CAR T); pivotal trial for IMPT-314 expected 2025.
- Cash runway post-close into 2027; transaction expected to close Q4 2024 subject to HSR clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312524242808/0001193125-24-242808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312524242808/d881076d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-242808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer